Thymic Cancer

Gleevec for thymic cancer

Thymic carcinomas (TC) are rare neoplastic diseases with chemosensitivity to a broad range of agents. Studies have demonstrated expression of c-kit in TC, presenting a potential target for drugs that inhibitor of the KIT tyrosine kinase receptor (TKR). Gleevec (Imatinib) is an orally administered inhibitor of multiple TKR’s, including bcr-abl, KIT, and PDGFR. Several case reports demonstrate responses of thymic tumors to imatinib. However, in 2008,

Read more